21Shares has launched a synthetic exchange-traded product (ETP) linked to Anthropic’s implied private valuation, giving investors access to a market-based measure of the AI company’s value before a potential initial public offering (IPO).
Announced on October 13, the 21Shares Anthropic Synthetic ETP, trading under ticker CLAU and ISIN CH1606386675, is listed on the Vienna MTF operated by Wiener Börse. 21Shares describes it as Europe’s first ETP offering continuous, unleveraged exposure to Anthropic’s implied valuation ahead of an IPO.
How CLAU Works
CLAU obtains its exposure through notes issued by 21Shares x FalconX Limited, a special-purpose vehicle (SPV) associated with 21Shares and FalconX. FalconX manages the underlying exposure through perpetual futures contracts, while the product references the Kaiko Anthropic USD Reference Rate (USDT).
According to 21Shares, the underlying exposure is sourced through total return swaps linked to the Kaiko index. The daily index reference price is derived from Binance’s Anthropic perpetual futures.
Binance’s derivatives market provides the reference pricing input, while the ETP obtains its exposure through a structured note and swap arrangement. Investors do not directly hold Anthropic futures or shares through the product. Kaiko’s reference rate is intended to provide a benchmark for the product’s net asset value (NAV). However, Anthropic’s private valuation is not continuously observable in a public spot market. 21Shares says its reference pricing relies on oracle infrastructure and order-book depth, introducing risks associated with how the underlying market is priced.
The structure also differs from perpetual contracts that settle or terminate when a company lists. 21Shares says CLAU is designed to continue trading through an Anthropic IPO without forced settlement or conversion into shares. If Anthropic becomes publicly listed, the reference price used by the underlying futures positions is intended to transition to the company’s exchange-quoted spot price. That means the product can continue offering synthetic exposure after a listing, but it does not turn into an Anthropic shareholding.
In terms of product figures, the product page reported a NAV of $9.88 per unit and assets under management (AUM) of approximately $49,397, with 5,000 securities outstanding. Those figures were displayed for October 12, ahead of the October 13 public launch announcement. The numbers offer an early snapshot of the product’s size, but they do not establish broader investor demand or indicate how much trading activity it will attract.
Virtu Financial Ireland is listed as the product’s authorized participant and market maker, according to the product page.
Access to a Private Valuation, Not Private Shares
21Shares says the ETP is intended to address the difficulty investors face in accessing private-company exposure before an IPO. Participation in private funding rounds and secondary-market transactions can depend on investor eligibility, minimum investment sizes and access to specialist platforms.
Duncan Moir, president and chief investment officer at 21Shares, said traditional investors face a growing access problem as companies develop substantial value while remaining private. He said the ETP structure applies tools developed in digital assets to alternative and multi-asset investing.
Austin Reid, chief commercial and strategy officer at FalconX, said the launch responds to investor demand for exposure to market segments that are otherwise difficult to access.
But the accessibility claim needs to be understood in context. A listed ETP may be easier to trade through a brokerage account than a private-market investment, yet its performance depends on a synthetic reference asset and a derivatives-based structure. Easier access does not remove the risks associated with the underlying valuation.
What Investors Are Buying
The product’s synthetic structure is central to understanding what CLAU offers. According to 21Shares’ product documentation, the ETP does not provide direct ownership of Anthropic shares, does not confer shareholder rights and is not affiliated with or endorsed by Anthropic.
Instead, investors receive exposure to a market-implied valuation through notes issued by FalconX, which acts as the counterparty and manages the underlying perpetual-futures exposure. Investors therefore face counterparty risk in addition to the market risk associated with Anthropic’s implied valuation.
The structure also creates a potential conflict of interest because FalconX is identified in the product documentation as 21Shares’ parent company as well as the note counterparty. Investors should review the product’s prospectus and final terms to understand the legal obligations, recourse provisions, and risks applicable to the notes.
CLAU carries a 1.00% annual product fee, according to the product page. The issuer also says financing, trading and perpetual-funding costs can pass through to the NAV, meaning the product’s total cost can vary with the underlying derivatives markets. The launch announcement also lists a 2.00% exit fee. That charge is not prominently displayed alongside the annual product fee on the product page reviewed for this article. Investors should consult the official product documents and applicable final terms to confirm all charges before investing.
The product is also subject to geographic and investor restrictions. The issuer says marketing in Switzerland and the United Kingdom is restricted to professional investors, while its European offering is governed by the relevant prospectus and final terms. The product has not been registered under the U.S. Securities Act and may not be offered in the United States, Canada, Australia, or Japan, according to the launch materials.
Pre-IPO Derivatives Bring Valuation Risk Into a Listed Product
CLAU’s structure connects traditional exchange-traded products with a growing market for derivatives tied to private-company valuations. Perpetual futures can provide a reference price where a conventional public spot market does not exist, but their prices can move with sentiment, trading depth, and funding conditions rather than verified transactions in the company’s shares.
That risk is particularly relevant when a private company’s potential IPO valuation is contested. Research firm New Constructs described Anthropic’s reported path to a $2 trillion valuation as the “most ridiculous IPO of 2026” in an analysis. The firm questioned whether the company’s reported financial performance and future commitments supported such a valuation. Its assessment represents the firm’s view, rather than an established market consensus.
Anthropic’s reported revenue growth and position in the AI market have helped drive investor interest, while its reported losses and future infrastructure commitments have prompted questions about profitability and valuation. The financial figures cited in public commentary should be treated as reported figures, not as independently verified projections of what the company will be worth at an IPO.
CLAU does not settle that debate. It gives investors a listed instrument through which to take exposure to a derivatives-based estimate of Anthropic’s valuation, leaving them exposed to changes in that estimate and to the structure used to deliver the exposure.
Why the Launch Matters
The CLAU launch illustrates how crypto-market infrastructure is being incorporated into products offered through traditional financial venues. Perpetual futures traded on a crypto exchange supply the reference pricing input; Kaiko provides the index; and a note and swap structure delivers synthetic exposure through a listed ETP.
For investors, the distinction between access and ownership remains critical. CLAU may offer a brokerage-accessible way to follow Anthropic’s implied valuation before an IPO, but it does not provide shares, voting rights or a claim on the company’s assets. Its value instead depends on the underlying reference price, the derivatives structure and the obligations of the counterparty. The result is a new route to pre-IPO exposure, with the valuation uncertainty and structural risks of synthetic derivatives still firmly in place.
Also Read: Hong Kong to List Second Solana Spot ETF on October 13
